

ASX Announcement

New Family 4 Patent to be Granted for RECCE® Anti-Infectives

Sydney Australia, 11 April 2023: Recce Pharmaceuticals Limited (**ASX:RCE**, **FSE:R9Q**), the Company developing a New Class of Synthetic Anti-Infectives, is pleased to announce the Australian Patent Office issued notification of intent to grant the first of Recce's new Patent Family 4 for RECCE's anti-infectives "*Process for Preparation of Biologically Active Copolymer*", expiry 2041.

The Australian Patent claims relate to RECCE® 327 (R327) and RECCE® 529 (R529), most notably:

- Process for preparation of RECCE® anti-infectives
- Use of R327/R529 for the treatment of disease, particularly in treatment of bacterial infections, viral infections and more
 - Specifically, further validating RECCE® anti-infectives from studies in **Burn Wounds, Urinary Tract Infections, Gonorrhoea, Influenza, SARS-CoV-2** and more (bacterial/viral pathogen examples below)
- Administration by oral, inhalation, transdermal delivery or by injection (into the blood stream, intramuscular and/or intravenous)
- Administration may also be applied as an aerosol, gel, topical foam or ointment (or impregnated into a dressing for application to skin or mucous membranes for transdermal or transmucosal delivery)

This is the first of Recce's wholly-owned Family 4 patents accepted with Intention to Grant, with Patent Cooperation Treaty Country (PCT) patent submissions in respective stages of review.

Chief Executive Officer, James Graham said: "With now over 40 patents around the world, validation of Recce's New Class of Anti-infectives marketing/manufacturing monopolies to at least January 2041 are again welcomed as an addition to its intellectual property portfolio globally."



ASX: RCE, **FSE:** R9Q

Head Office: Level 23, 180 George St, Salesforce Tower, SYDNEY NSW 2000 **T** +61 (02) 9256 2505

R&D Centre - Perth: Suite 10, 3 Brodie Hall Drive, Technology Park, BENTLEY WA 6102 **T** +61 (8) 9362 9860

Washington Office: 1717 Pennsylvania Avenue NW, Suite 1025, WASHINGTON DC 20006 USA

Bacterial Pathogens Covered in Family 4

Specific examples of such bacterial infections may be selected from the group of bacteria consisting of *Proteus spp*, *Serratia spp*, *Pseudomonas aeruginosa*, *Neisseria meningitidis*, *Escherichia coli*, *Klebsiella pneumoniae*, *Staphylococcus aureus*, coagulase-negative *Staphylococcus spp*, *Streptococcus pyogenes*, *Streptococcus pneumoniae* and *Enterococcus spp*.

Viral Pathogens Covered in Family 4

Examples of viral infections may be caused by a range of viruses such as coated viruses (e.g., lipid coated viruses) including herpes, HIV, cytomegalovirus and influenza. Preferably, the viral infection treated and/or controlled by the method of the invention may be HSV-1, HSV-2, Varicella Zoster Virus (in the form of chicken pox or shingles), HCMV, EBV, Herpes 6, Herpes 7, Herpes 8 and SARS-CoV-2. Other examples include Influenza A, Ross River virus, Coronavirus including Coronaviruses responsible for severe acute respiratory syndrome and, SARS-CoV-2 also generally referred to as COVID-19.

This announcement has been approved for release by Recce Pharmaceuticals Board.

About Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd (ASX: **RCE**, FSE: **R9Q**) is developing a New Class of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens.

Recce's anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: RECCE® 327 as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria including their superbug forms; RECCE® 435 as an orally administered therapy for bacterial infections; and RECCE® 529 for viral infections. Through their multi-layered mechanisms of action, Recce's anti-infectives have the potential to overcome the hypercellular mutation of bacteria and viruses – the challenge of all existing antibiotics to date.

The FDA has awarded RECCE® 327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act – labelling it for Fast Track Designation, plus 10 years of market exclusivity post approval. Further to this designation, RECCE® 327 has been included on The Pew Charitable Trusts Global New Antibiotics in Development Pipeline as the world's only synthetic polymer and sepsis drug candidate in development. RECCE® 327 is not yet market approved for use in humans with further clinical testing required to fully evaluate safety and efficacy.

Recce wholly owns its automated manufacturing, which is supporting present clinical trials. Recce's anti-infective pipeline seeks to exploit the unique capabilities of its technologies targeting synergistic, unmet medical needs.



Chief Executive Officer
James Graham
Recce Pharmaceuticals Ltd
james.graham@recce.com.au

Australia
Andrew Geddes
CityPR
+61 408 677 734
ageddes@citypublicrelations.com.au

Media and Investor Relations

USA
Jordyn Temperato
LifeSci Communications
jtemperato@lifescicomms.com

Europe
Guillaume van Renterghem
LifeSci Advisors
gvanrenterghem@lifesciadvisors.com